Identification and validation of Triamcinolone and Gallopamil as treatments for early COVID-19 via an in silico repurposing pipeline

Title Identification and validation of Triamcinolone and Gallopamil as treatments for early COVID-19 via an in silico repurposing pipeline Author list Méabh MacMahonabm, Woochang Hwangam, Soorin Yimc, Eoghan MacMahond, Alexandre Abrahame, Justin Bartonf, Mukunthan Tharmakulasingamg, Paul Bilokonhij, Vasanthi Priyadarshini Gaddik, Namshik Hanal* Affiliations a. Milner Therapeutics Institute, University of Cambridge, Cambridge, UK b. Centre for Therapeutics Discovery, LifeArc, Stevenage, UK c. Department of Bio and Brain Engineering, KAIST, Daejeon, Republic of Korea d. UCD School of Chemistry, University College Dublin, Dublin, Ireland e. Dataiku, Paris, France f. Institute of Structural and Molecular Biology, Birkbeck, University of London, London, UK g. Centre for Vision, Speech and Signal Processing, University of Surrey, Guildford, UK h. Department of Computing, Imperial College London, London, UK i. Department of Mathematics, Imperial College London, London, UK j. Thalesians Ltd, London, UK k. Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

[1]  A. Orekhov,et al.  ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease , 2016, Laboratory Investigation.

[2]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[3]  George M. Varghese,et al.  Clinical management of COVID-19 , 2020, The Indian journal of medical research.

[4]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[5]  S. Ciesek,et al.  Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.

[6]  Madeleine K. D. Scott,et al.  Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.

[7]  Nicholas M Katritsis,et al.  Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies , 2020, bioRxiv.

[8]  M. Dimopoulos,et al.  Pulmonary toxicity from novel antineoplastic agents. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[10]  Gary D Bader,et al.  Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap , 2019, Nature Protocols.

[11]  B. Baradaran,et al.  The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV , 2021, Archives of virology.

[12]  Albert-László Barabási,et al.  Network-based prediction of drug combinations , 2019, Nature Communications.

[13]  Yoshinobu Nakanishi,et al.  Induction of Apoptosis and Subsequent Phagocytosis of Virus-Infected Cells As an Antiviral Mechanism , 2017, Front. Immunol..

[14]  Jing Shi,et al.  Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.

[15]  P. Larsen,et al.  Thyroid dysfunction from antineoplastic agents. , 2011, Journal of the National Cancer Institute.

[16]  Tina Ritschel,et al.  Molecular interaction fingerprint approaches for GPCR drug discovery. , 2016, Current opinion in pharmacology.

[17]  Andrew R. Leach,et al.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.

[18]  W. Shrank,et al.  Pricing of monoclonal antibody therapies: higher if used for cancer? , 2018, The American journal of managed care.

[19]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[20]  Kevin Bretonnel Cohen,et al.  Natural Language Processing for Rapid Response to Emergent Diseases: Case Study of Calcium Channel Blockers and Hypertension in the COVID-19 Pandemic , 2020, Journal of medical Internet research.

[21]  David Weininger,et al.  SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..

[22]  D. McGonagle,et al.  The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.

[23]  M. Sanson,et al.  Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability , 2017, Acta oncologica.

[24]  V. Calvez,et al.  Performance of serum apolipoprotein-A1 as a sentinel of Covid-19 , 2020, medRxiv.

[25]  Vinay Prasad,et al.  Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval , 2017, JAMA internal medicine.

[26]  Fang Li,et al.  Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[27]  Julian Druce,et al.  Induction of Apoptosis by the Severe Acute Respiratory Syndrome Coronavirus 7a Protein Is Dependent on Its Interaction with the Bcl-XL Protein , 2007, Journal of Virology.

[28]  Károly Héberger,et al.  Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? , 2015, Journal of Cheminformatics.

[29]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[30]  Carlos Del Rio,et al.  Mild or Moderate Covid-19. , 2020, The New England journal of medicine.

[31]  A. Fauci,et al.  Emerging Pandemic Diseases: How We Got to COVID-19 , 2020, Cell.

[32]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[33]  C. Hopkins,et al.  Anosmia and loss of smell in the era of covid-19 , 2020, BMJ.

[34]  Ashutosh Kumar,et al.  Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery , 2018, Front. Chem..

[35]  J. Vilo,et al.  g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) , 2019, Nucleic Acids Res..

[36]  F. Laurent,et al.  Calcium channel blocker reduces airway remodeling in severe asthma. A proof-of-concept study. , 2015, American journal of respiratory and critical care medicine.

[37]  P. Auewarakul,et al.  Influence of cellular lipid content on influenza A virus replication , 2020, Archives of Virology.

[38]  Guiqiang Wang,et al.  Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality , 2020, International Journal of Antimicrobial Agents.

[39]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.